1-[2-羟基-4-(羟甲基)苯基]乙酮 | 22518-00-9

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-[2-羟基-4-(羟甲基)苯基]乙酮
• 英文名称: 1-[2-hydroxy-4-(hydroxymethyl)phenyl]ethan-1-one
• 英文别名: 2-hydroxy-4-methylene-hydroxyacetophenone；2-Acetyl-5-hydroxymethyl-phenol；1-[2-Hydroxy-4-(hydroxymethyl)phenyl]ethanone
• CAS: 22518-00-9
• 化学式: C₉H₁₀O₃
• 分子量: 166.177
• InChiKey: CEKCNQSWPNISHG-UHFFFAOYSA-N

物化性质

• 熔点：
  61.5–62°C
• 沸点：
  344.2±32.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[2-羟基-4-(羟甲基)苯基]乙酮 在 咪唑 、 magnesium 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 6-methyl-2-[2-(triisopropylsilanyloxy)-4-(triisopropylsilanyloxymethyl)phenyl]hept-5-en-2-ol
  参考文献：
  名称：

  莪术四醇的分离、结构解析与合成

  摘要：

  新的天然产物 (+)-curcutetraol 和 (-)-curcutriolamide 从细菌 CNH-741 和真菌 CNC-979 中分离出来，从海洋沉积物中分离出来。(+)-Curcutetraol 是一种极性化合物，在单个立体中心含有叔苄醇部分，通过避免在硅胶上进行色谱，保留而没有外消旋化。(+)-curcutetraol 的绝对构型是通过将其实验 CD 光谱与量子化学 CD 计算预测的光谱进行比较来确定的。来自海洋来源的酚类红没药烷倍半萜类化合物以前仅从柳珊瑚和海绵中获知。已开发出外消旋姜黄醇的短程全合成。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

  DOI：

  10.1002/ejoc.200400336
• 作为产物：
  描述：

  1-[2-acetoxy-4-(bromomethyl)phenyl]ethan-1-one 在 sodium hydroxide 作用下， 反应 12.0h， 以54%的产率得到1-[2-羟基-4-(羟甲基)苯基]乙酮
  参考文献：
  名称：

  莪术四醇的分离、结构解析与合成

  摘要：

  新的天然产物 (+)-curcutetraol 和 (-)-curcutriolamide 从细菌 CNH-741 和真菌 CNC-979 中分离出来，从海洋沉积物中分离出来。(+)-Curcutetraol 是一种极性化合物，在单个立体中心含有叔苄醇部分，通过避免在硅胶上进行色谱，保留而没有外消旋化。(+)-curcutetraol 的绝对构型是通过将其实验 CD 光谱与量子化学 CD 计算预测的光谱进行比较来确定的。来自海洋来源的酚类红没药烷倍半萜类化合物以前仅从柳珊瑚和海绵中获知。已开发出外消旋姜黄醇的短程全合成。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

  DOI：

  10.1002/ejoc.200400336

文献信息

• Synthesis of 6<i>H</i>-Benzo[<i>c</i>]chromenes via Palladium-Catalyzed Intramolecular Dehydrogenative Coupling of Two Aryl C–H Bonds
  作者：Dong-Dong Guo、Bin Li、Da-Yu Wang、Ya-Ru Gao、Shi-Huan Guo、Gao-Fei Pan、Yong-Qiang Wang

  DOI：10.1021/acs.orglett.6b03763

  日期：2017.2.17

  features broad substrate scope and good tolerance of functional groups and uses molecular oxygen as the terminal oxidant. The high efficiency of the approach is verified by concise total synthesis of natural product cannabinol.

  首次报道了钯催化的两个简单的芳烃分子内CH-H / CH-H偶联反应，生成6 H-苯并[ c ]苯并二甲基苯。该方法具有广泛的底物范围和对官能团的良好耐受性，并使用分子氧作为末端氧化剂。天然产物大麻酚的简明全合成证明了该方法的高效率。
• Bohlmann,F. et al., Chemische Berichte, 1969, vol. 102, p. 864 - 871
  作者：Bohlmann,F. et al.

  DOI：——

  日期：——
• PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-HYDROXY-1,2-BEZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS
  申请人：TOYAMA CHEMICAL CO., LTD.

  公开号：EP1988085B1

  公开（公告）日：2014-11-12
• Chiral Complexes of Ascorbic Acid with Natural Antioxidant and Anti-Inflammatory Ketones Including Aloe, Citrus, Ginger, and Mango for Skin and Hair Care
  申请人：GUPTA SHYAM K.

  公开号：US20110059907A1

  公开（公告）日：2011-03-10

  This invention relates to certain complexes of ascorbic acid and its derivatives with certain natural antioxidant and anti-inflammatory ketones for topical or oral application; said complexes having general chemical formula (I), its isomers, and salts thereof, including their optically active or racemic forms. This invention also relates to a method of treatment of skin condition, including dark skin, age spots, acne, inflammation, loss of cellular antioxidants, collagen loss with aging, loss of skin pliability, loss of skin suppleness, skin wrinkles, oxidation, damage from radiation, malfunction of matrix metalloproteases, malfunction of tyrosinases, damage from free radicals, photo-damage, nutritional deficiency, and combinations thereof;
• PHARMACEUTICAL COMPOSITION CONTAINING COMBINATION EXTRACTS OF MOUTAN ROOT BARK, ANGELICA DAHURICA ROOT, BUPLEURUM ROOT OR FRACTIONS THEREOF FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDER
  申请人：UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

  公开号：US20170224754A1

  公开（公告）日：2017-08-10

  The present invention relates to a pharmaceutical composition for treating and preventing degenerative neurological disorders, containing, as an active ingredient, a mixture extract of two or more types selected from the group consisting of Moutan Root Bark, Angelica Dahurica Root, and Bupleurum Root, or a fraction thereof. Specifically, the extract of the mixture of the present invention exhibits a recovery effect on mitochondrial function damage, a relieving effect on endoplasmic reticulum stress and also exhibits simultaneously an inhibitory effect on inflammatory response, which are remarkably improved compared with those exhibited in an in vitro single extract, and the extract of the mixture significantly exhibits an improvement effect on motor coordination and a protective effect on dopaminergic neurons in a Parkinson's disease animal model, and thus the extract of the mixture of the present invention or a fraction thereof can be useful as an active ingredient of a pharmaceutical composition for treating and preventing degenerative neurological disorders.